Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEN 3014

Next Previous
Drug Profile

GEN 3014

Alternative Names: GEN-3014; HexaBody®-CD38

Latest Information Update: 31 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genmab
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Complement activation stimulants; Immunomodulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 31 Jul 2025 Genmab completes a phase-I/II trials in Haematological malignancies (Second-line therapy or greater) in US, Denmark, Sweden, Australia, Netherlands, Poland, Spain, France and Greece, Bosnia and Herzegovina, Czechia, Georgia, Malaysia, Moldova, South Korea, New Zealand, North Macedonia, Philippines, Ukraine and Hungary (IV) (EUCT2020-003781-40) (NCT04824794)
  • 10 Mar 2025 Johnson & Johnson decides to not exercise its option to receive a worldwide license to develop, manufacture and commercialize GEN 3014
  • 10 Mar 2025 Discontinued - Phase-I/II for Haematological malignancies (Second-line therapy or greater) in Ukraine, Philippines, Macedonia, New Zealand, Moldova, Malaysia, South Korea, Hungary, Georgia, Czech Republic, Bosnia-Herzegovina, Greece, France, Spain, Poland, Netherlands, Australia, USA, Sweden, Denmark (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top